Factors influencing immunologic response to hepatitis B vaccine in adults

被引:132
作者
Yang, Shigui [1 ]
Tian, Guo [1 ]
Cui, Yuanxia [1 ]
Ding, Cheng [1 ]
Deng, Min [1 ]
Yu, Chengbo [1 ]
Xu, Kaijin [1 ]
Ren, Jingjing [1 ]
Yao, Jun [2 ]
Li, Yiping [3 ]
Cao, Qing [1 ]
Chen, Ping [1 ]
Xie, Tiansheng [1 ]
Wang, Chencheng [1 ]
Wang, Bing [1 ]
Mao, Chen [4 ,5 ]
Ruan, Bing [1 ]
Jiang, Tian'an [6 ]
Li, Lanjuan [1 ]
机构
[1] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis, Affiliated Hosp 1,Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310051, Zhejiang, Peoples R China
[3] Zhejiang Inst Med Care Informat Technol, Hangzhou 311112, Zhejiang, Peoples R China
[4] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Div Epidemiol, Hong Kong, Hong Kong, Peoples R China
[5] Chinese Univ Hong Kong Shenzhen, Shenzhen Res Inst, Shenzhen Municipal Key Lab Hlth Risk Anal, Shenzhen, Guangdong, Peoples R China
[6] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Ultrasound, Hangzhou 310003, Zhejiang, Peoples R China
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
关键词
HEALTH-CARE WORKERS; IMMUNOGLOBULIN PRODUCTION; OUTBREAK RESPONSE; IMMUNE-RESPONSE; IMMUNOGENICITY; VIRUS; SAFETY; IMMUNIZATION; EFFICACY; PROGRAM;
D O I
10.1038/srep27251
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hepatitis B was still a worldwide health problem. This study aimed to conducted a systematic review and meta-analysis to assess a more precise estimation of factors that influence the response to hepatitis B vaccine in adults. Our included studies examined seroprotection rates close to the end of vaccination schedules in healthy adult populations. This meta-analysis including 21053 adults in 37 articles showed that a significantly decreased response to hepatitis B vaccine appeared in adults (age >= 40) (RR: 1.86, 95% CI: 1.55-2.23), male adults (RR: 1.40, 95% CI: 1.22-1.61), BMI >= 25 adults (RR: 1.56, 95% CI: 1.12-2.17), smoker (RR: 1.53, 95% CI: 1.21-1.93), and adults with concomitant disease (RR: 1.39, 95% CI: 1.04-1.86). Meanwhile, we further found a decreased response to hepatitis B vaccine appeared in adults (age >= 30) (RR: 1.77, 95% CI: 1.48-2.10), and adults (age >= 60) (RR: 1.30, 95% CI: 1.01-1.68). However, there were no difference in response to hepatitis B vaccine both in alcoholic (RR: 0.90, 95% CI: 0.64-1.26) and 0-1-12 vs. 0-1-6 vaccination schedule (RR: 1.39, 95% CI: 0.41-4.67). Pooling of these studies recommended the sooner the better for adult hepatitis B vaccine strategy. More vaccine doses, supplemental/additional strengthening immunity should be emphasized on the susceptible population of increasing aged, male, BMI >= 25, smoking and concomitant disease. The conventional 0-1-6 vaccination schedule could be still worth to be recommended.
引用
收藏
页数:12
相关论文
共 58 条
  • [1] Immunogenicity of hepatitis B vaccines - Implications for persons at occupational risk of hepatitis B virus infection
    Averhoff, F
    Mahoney, F
    Coleman, P
    Schatz, G
    Hurwitz, E
    Margolis, H
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 1998, 15 (01) : 1 - 8
  • [2] Hepatitis B vaccine immunogenicity among adults vaccinated during an outbreak response in an assisted living facility-Virginia, 2010
    Bender, Thomas John
    Sharapov, Umid
    Utah, Okey
    Xing, Jian
    Hu, Dale
    Rybczynska, Jolanta
    Drobeniuc, Jan
    Kamili, Saleem
    Spradling, Philip R.
    Moorman, Anne C.
    [J]. VACCINE, 2014, 32 (07) : 852 - 856
  • [3] Immunogenicity of a recombinant hepatitis a vaccine in adults
    Bock, HL
    Kruppenbacher, J
    Sanger, R
    Hobel, W
    Clemens, R
    Jilg, W
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (19) : 2226 - 2231
  • [4] Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose
    Bruce, Michael G.
    Bruden, Dana
    Hurlburt, Debby
    Zanis, Carolyn
    Thompson, Gail
    Rea, Lisa
    Toomey, Michele
    Townshend-Bulson, Lisa
    Rudolph, Karen
    Bulkow, Lisa
    Spradling, Philip R.
    Baum, Richard
    Hennessy, Thomas
    McMahon, Brian J.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (01) : 16 - 22
  • [5] Cardell K, 1999, SCAND J INFECT DIS, V31, P197, DOI 10.1080/003655499750006272
  • [6] Immune response to hepatitis B vaccine in a group of health care workers in Sri Lanka
    Chathuranga, L. S.
    Noordeen, F.
    Abeykoon, A. M. S. B.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (11) : E1078 - E1079
  • [7] Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults
    Cinza Estevez, Zurina
    Aguilar Betancourt, Aristides
    Muzio Gonzalez, Verena
    Figueroa Baile, Nelvis
    Valenzuela Silva, Carmen
    Hernandez Bernal, Francisco
    Penton Arias, Eduardo
    Delhanty Fernandez, Aurora
    Martin Olazabal, Nelia
    del Rio Martin, Amaurys
    Leal Batista, Lester
    Veliz Rios, Gloria
    Hernandez Hernandez, Hctor
    Blanco Hernandez, Aracelis
    Perez Lugo, Evelyn
    de la Torre Cruz, Joel
    Batista Marchec, Bertha L.
    Alvarez Falcon, Leovaldo
    Trujillo Brito, Jannet
    Ortega Leon, Darien
    Lopez Saura, Pedro
    [J]. BIOLOGICALS, 2007, 35 (02) : 115 - 122
  • [8] IMMUNOGENICITY OF YEAST-DERIVED HEPATITIS-B VACCINE FROM 2 DIFFERENT PRODUCERS
    DAHLHANSEN, E
    SIEBKE, JC
    FROLAND, SS
    DEGRE, M
    [J]. EPIDEMIOLOGY AND INFECTION, 1990, 104 (01) : 143 - 149
  • [9] Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers
    De Schryver, A.
    Verstrepen, K.
    Vandersmissen, L.
    Vandermeeren, N.
    Vernaillen, I.
    Vranckx, R.
    Van Damme, P.
    van Sprundel, M.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) : e5 - e10
  • [10] LONG-TERM IMMUNOGENICITY SAFETY AND EFFICACY OF A RECOMBINANT HEPATITIS-B VACCINE IN HEALTHY-ADULTS
    DENTICO, P
    BUONGIORNO, R
    VOLPE, A
    ZAVOIANNI, A
    PASTORE, G
    SCHIRALDI, O
    [J]. EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1992, 8 (05) : 650 - 655